Quantum Genomics Société Anonyme (ALQGC.PA)
EUR 0.07
(0.0%)
EUR 0.07
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.74 Million EUR | -84.16% |
| 2022 | 23.65 Million EUR | 11.37% |
| 2021 | 21.24 Million EUR | -35.24% |
| 2020 | 32.8 Million EUR | 121.95% |
| 2019 | 14.77 Million EUR | -20.03% |
| 2018 | 18.48 Million EUR | 32.79% |
| 2017 | 13.91 Million EUR | -4.08% |
| 2016 | 14.5 Million EUR | 37.65% |
| 2015 | 10.54 Million EUR | 121.78% |
| 2014 | 4.75 Million EUR | 180.76% |
| 2013 | 1.69 Million EUR | 60.21% |
| 2012 | 1.05 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 891.68 Thousand EUR | 0.0% |
| 2023 FY | 3.74 Million EUR | -84.16% |
| 2023 Q4 | 3.74 Million EUR | 0.0% |
| 2023 Q2 | 5.75 Million EUR | 0.0% |
| 2022 Q2 | 27.05 Million EUR | 0.0% |
| 2022 FY | 23.65 Million EUR | 11.37% |
| 2022 Q4 | 23.65 Million EUR | 0.0% |
| 2021 FY | 21.24 Million EUR | -35.24% |
| 2021 Q2 | 32.41 Million EUR | 0.0% |
| 2021 Q4 | 21.24 Million EUR | 0.0% |
| 2020 Q4 | 32.8 Million EUR | 0.0% |
| 2020 FY | 32.8 Million EUR | 121.95% |
| 2020 Q2 | 18.54 Million EUR | 0.0% |
| 2019 FY | 14.77 Million EUR | -20.03% |
| 2019 Q2 | 16.58 Million EUR | 0.0% |
| 2019 Q4 | 15.1 Million EUR | 0.0% |
| 2018 Q4 | 18.48 Million EUR | 0.0% |
| 2018 FY | 18.48 Million EUR | 32.79% |
| 2018 Q2 | 9.67 Million EUR | 0.0% |
| 2017 Q2 | 10.69 Million EUR | 0.0% |
| 2017 FY | 13.91 Million EUR | -4.08% |
| 2017 Q4 | 13.91 Million EUR | 0.0% |
| 2016 Q2 | 15.84 Million EUR | 0.0% |
| 2016 FY | 14.5 Million EUR | 37.65% |
| 2016 Q4 | 14.5 Million EUR | 0.0% |
| 2015 Q4 | 10.54 Million EUR | 0.0% |
| 2015 Q2 | 12.89 Million EUR | 0.0% |
| 2015 FY | 10.54 Million EUR | 121.78% |
| 2014 Q4 | 4.75 Million EUR | 0.0% |
| 2014 Q2 | 2.74 Million EUR | 0.0% |
| 2014 FY | 4.75 Million EUR | 180.76% |
| 2013 FY | 1.69 Million EUR | 60.21% |
| 2013 Q4 | 1.69 Million EUR | 0.0% |
| 2012 FY | 1.05 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 74.529% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 98.854% |
| Adocia SA | 24.95 Million EUR | 84.986% |
| Aelis Farma SA | 26.28 Million EUR | 85.743% |
| Biophytis S.A. | 11.93 Million EUR | 68.609% |
| Advicenne S.A. | 12.4 Million EUR | 69.801% |
| genOway Société anonyme | 31.84 Million EUR | 88.233% |
| IntegraGen SA | 8 Million EUR | 53.167% |
| Medesis Pharma S.A. | 1.92 Million EUR | -94.503% |
| Neovacs S.A. | 47.53 Million EUR | 92.118% |
| NFL Biosciences SA | 3.97 Million EUR | 5.638% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 74.876% |
| Sensorion SA | 46.49 Million EUR | 91.941% |
| Theranexus Société Anonyme | 7.23 Million EUR | 48.233% |
| TME Pharma N.V. | 2.49 Million EUR | -50.412% |
| Valbiotis SA | 33.24 Million EUR | 88.731% |
| TheraVet SA | 7.53 Million EUR | 50.27% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 89.378% |
| argenx SE | 4.11 Billion EUR | 99.909% |
| BioSenic S.A. | 9.55 Million EUR | 60.804% |
| Celyad Oncology SA | 16.28 Million EUR | 76.988% |
| DBV Technologies S.A. | 165.65 Million USD | 97.738% |
| Galapagos NV | 4.35 Billion EUR | 99.914% |
| Genfit S.A. | 173.87 Million EUR | 97.845% |
| GeNeuro SA | 6.31 Million EUR | 40.649% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 92.142% |
| Innate Pharma S.A. | 184.19 Million EUR | 97.966% |
| Inventiva S.A. | 69.13 Million EUR | 94.581% |
| MaaT Pharma SA | 42.93 Million EUR | 91.273% |
| MedinCell S.A. | 36.94 Million EUR | 89.859% |
| Nanobiotix S.A. | 93.89 Million EUR | 96.01% |
| Onward Medical N.V. | 43.62 Million EUR | 91.412% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 96.495% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 95.425% |
| Oxurion NV | 6.55 Million EUR | 42.797% |
| Pharming Group N.V. | 426.33 Million EUR | 99.121% |
| Poxel S.A. | 4.82 Million EUR | 22.315% |
| GenSight Biologics S.A. | 9.08 Million EUR | 58.768% |
| Transgene SA | 45.21 Million EUR | 91.714% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.805% |
| UCB SA | 15.53 Billion EUR | 99.976% |
| Valneva SE | 469.39 Million EUR | 99.202% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 87.847% |